Form 4: UTHR CEO Exercises, Sells Shares Under 10b5-1 Plan

United Therapeutics Corp. CEO Martine A. Rothblatt exercised and sold common stock options totaling 8,000 shares over two days in December 2025, pursuant to a pre-arranged trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (UTHR), executed transactions involving the company's common stock on December 11 and December 12, 2025.
• These transactions were conducted under a pre-arranged 10b5-1 trading plan established on May 2, 2025.
• On December 11, 2025, Rothblatt exercised 4,000 stock options at an exercise price of $120.26 per share.
• Concurrently on December 11, 2025, Rothblatt sold a total of 4,000 common shares at weighted average prices of $483.1213, $484.3036, and $485.14.
• On December 12, 2025, Rothblatt exercised an additional 4,000 stock options at an exercise price of $120.26 per share.
• Also on December 12, 2025, Rothblatt sold a total of 4,000 common shares at weighted average prices of $489.9533 and $490.9772.
• Following these transactions, Rothblatt directly holds 130 common shares and 18,000 stock options.
• Indirect holdings include 166 shares by spouse and 639,193 shares across various family trusts.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan, mitigating concerns of opportunistic selling. The exercise of options at a significantly lower price than the sale price indicates a positive outcome for the executive, reflecting the company's stock appreciation.

Positives

• The exercise of stock options indicates that the options were in-the-money, allowing the reporting person to realize a gain.
• The sale prices of the common stock (ranging from approximately $483 to $491) are significantly higher than the exercise price of $120.26, indicating substantial profitability from the option exercises.
• The transactions were executed under a pre-arranged 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations and suggests a planned, rather than opportunistic, sale.

Negatives

• The sale of 8,000 shares by a key executive (Chairperson & CEO) could be perceived as a negative signal by some investors, even if executed under a 10b5-1 plan.
• The direct beneficial ownership of common stock decreased to 130 shares following these transactions, although significant indirect holdings remain.

Future Outlook

The pre-arranged 10b5-1 trading plan, under which these transactions occurred, is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.

Industry Context

This Form 4 filing details routine insider transactions under a pre-arranged trading plan, which is a common practice for executives to manage their equity holdings and diversify their portfolios. It does not provide specific insights into broader industry trends or competitive landscape.

Related Party Transactions

• Shares are held indirectly by spouse (166 shares).
• Shares are held indirectly in various family trusts (totaling 639,193 shares), some of which the Reporting Person shares investment power, is a beneficiary, or whose spouse is a trustee/beneficiary.

Stakeholder Impact

• Shareholders: May view the planned sale by the CEO as a routine diversification event, especially given the 10b5-1 plan. The significant profit realized by the CEO from option exercises could be seen as a positive reflection of stock performance.

Next Steps

• The 10b5-1 trading plan will continue until the earlier of the exhaustion of 294,000 stock options expiring March 15, 2026, or December 31, 2025.

Key Dates

Recommendation

This Form 4 filing details routine, pre-planned insider transactions by the CEO, involving the exercise of stock options and subsequent sale of shares. While the sales are significant in volume, they were executed under a 10b5-1 plan, which typically signals a non-event for fundamental analysis as it's a pre-scheduled liquidity event rather than a reaction to new information. The transactions do not provide new insights into the company's operational performance, financial health, or strategic direction. Therefore, based solely on this filing, there is no new information to warrant a change in investment recommendation; a 'hold' stance is appropriate as investors should rely on broader company fundamentals and market conditions.

Keywords

United Therapeutics, UTHR, Martine A. Rothblatt, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Share Sale, CEO, Director, Beneficial Ownership